Buy TNXP by Jul 3, 2026.

TONMYA’s launch is rapidly inflecting into what could become one of the most overlooked commercial ramps in small-cap biotech. For the week ended March 20, 2026, Symphony reported 572 TRx / 465 NRx and $935K in weekly gross sales, a sharp +23.8% WoW increase from $755K the prior week. Importantly, as previously validated in prior company reporting, Symphony does not capture 100% of channel sales, making the company’s established 1.5x adjustment highly relevant—implying true weekly gross sales of \~$1.40M, or …